The roles of CyPA and CD147 in cardiac remodelling

• Published in: Experimental and molecular pathology Vol. 104; no. 3; pp. 222 - 226
• Main Authors: Su, Hongyan, Yang, Yi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.06.2018
• Subjects: Cardiac remodelling; CD147 (EMMPRIN); Cyclophilin A (CyPA); CD147 (EMMPRIN); Cardiac remodelling; Cyclophilin A (CyPA)
• ISSN: 0014-4800; 1096-0945
• DOI: 10.1016/j.yexmp.2018.05.001

Cyclophilin A (CyPA), an abundantly expressed protein belonging to the immunophilin family, is involved in a variety of physiological and pathological activities together with its extracellular receptor, CD147. Many studies have provided compelling evidence supporting critical roles of CyPA in immune and infectious diseases and malignant tumours. Recent studies have revealed that both CyPA and CD147 strongly promote cardiovascular inflammation, myocardial ischaemia-reperfusion injury, and myocardial remodelling processes. Here, we review the potential roles of CyPA and CD147 in cardiac remodelling and their implications for the development of novel pharmacological therapies for heart failure. •Recent studies have revealed that CyPA/CD147 signalling pathway plays important roles in cardiovascular diseases.•Both CyPA and CD147 appear to be suitable targets for the prevention and treatment of cardiac remodelling.•Further studies are needed to elucidate the underlying mechanisms of action of CyPA/CD147 under different conditions.